Kiora Pharmaceuticals, Inc. (KPRX)
Pre-Market:
| Previous Close | 0.5815 |
| Open | 0.6000 |
| Bid | 0.5363 x 100 |
| Ask | 0.5989 x 100 |
| Day's Range | 0.5230 - 0.6000 |
| 52 Week Range | 0.4510 - 2.2400 |
| Volume | |
| Avg. Volume | 222,009 |
| Market Cap | 14.966M |
| Beta (5Y Monthly) | -0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6900 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.67 |
NewsfileKiora Pharmaceuticals to Participate in Upcoming Investor Conferences
Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00 pm Eastern Time, Kiora's Executive Vice President of Finance, Melissa Tosca, will participate in the WeBull Corporate Connect Biotech Investment Webinar. The presentation will be available live from this
NewsfileKiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024Phase 2 clinical trial for KIO-104 for retinal inflammation expected to begin in 2025 Ended Q1 2024 with $31.3 million in cash and cash equivalents, providing an expected runway of more than two yearsEncinitas, California--(Newsfile Corp. - May 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces ...
NewsfileKiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
Encinitas, California--(Newsfile Corp. - May 8, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at The Citizens JMP Life Sciences Conference on Tuesday May 14th, 2024 at 1:00 pm EDT.Kiora's presentations can be accessed live from the homepage of the investor relations section on Kiora's website (ir.kiorapharma.com) and will be available for replay for 90 days on the investor relations "events" page.About Kiora PharmaceuticalsKiora Pharmace
